Preclinical and clinical studies on cancer-associated cachexia

Abstract

BACKGROUND: Cancer cachexia is the wasting condition that is often seen in advanced stage cancer patients. This wasting is largely attributable to a systemic and progressive loss of skeletal muscle mass that greatly hinders performance of normal daily activities, resulting in reduced quality of life. Moreover, it negatively influences the prognosis of cancer patients. A general consensus in the field is that the loss of muscle mass is due both to an increase in protein degradation and a decrease in protein synthesis. Recent studies using preclinical models for studying cachexia have been useful in identifying the contribution of inflammatory cytokines (e.g. tumor necrosis factor-α and Interleukin-6), and myostatin receptors (e.g. the type IIB activin receptor) to cachexia development, and have led to several clinical trials. However, many questions remain about the molecular mechanisms thought to play a role in the development of cachexia.

METHODS: We conducted a literature search using search engines, such as PubMed and Google Scholar to identify publications within the cancer cachexia field.

RESULTS: We summarized our current knowledge of: 1) the driving mechanisms of cancer cachexia, 2) the preclinical models available for studying the condition, and 3) the findings of recent clinical trials.

CONCLUSION: Cancer cachexia is a complex and variable condition that currently has no standard effective therapeutic treatment. Further studies are desperately needed to better understand this condition and develop effective combination treatments for patients.

Key words： cancer cachexia; muscle wasting; bodyweight loss; metabolic changes; increased protein degradation; decreased protein synthesis

Acknowledgements

This work is directly supported by National Cancer Institute Grants CA163124 (Y. Shiozawa), Department of Defense (W81XWH-14-1-0403 and W81XWH-17-1-0541, Y. Shiozawa), the Wake Forest Baptist Comprehensive Cancer Center Internal Pilot Funding (Y. Shiozawa), and the Wake Forest School of Medicine Internal Pilot Funding (Y. Shiozawa). Y. Shiozawa is supported as the Translational Research Academy which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001420. This work is also supported by the National Cancer Institute’s Cancer Center Support Grant award number P30CA012197 issued to the Wake Forest Baptist Comprehensive Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Compliance with ethics guidelines

D. Brooke Widner, D. Clark Files, Kathryn E. Weaver, Yusuke Shiozawa declare that they have no conflict of interest. All institutional and national guidelines for the care and use of laboratory animals were followed. This article does not contain any studies with human subjects performed by any of the authors.

References

1 Al-Majid S, Waters H (2008). The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs, 10(1): 7–20

PMID

2 Argilés J M, Busquets S, Stemmler B, López-Soriano F J (2014). Cancer cachexia: understanding the molecular basis. Nat Rev Cancer, 14(11): 754–762

PMID

3 Aulino P, Berardi E, Cardillo V M, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini E P, Baldi A, Faiola F, Adamo S, Coletti D (2010). Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer, 10(1): 363

PMID

4 Bayliss T J, Smith J T, Schuster M, Dragnev K H, Rigas J R (2011). A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther, 11(12): 1663–1668

PMID

5 Bennani-Baiti N, Walsh D (2009). What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb, 39(3): 257–262

PMID

6 Bilodeau P A, Coyne E S, Wing S S (2016). The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation. Am J Physiol Cell Physiol, 311(3): C392–C403

PMID

7 Bing C, Taylor S, Tisdale M J, Williams G (2001). Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem, 79(5): 1004–1012

PMID

8 Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris L G, Zimmers T A (2012). JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab, 303(3): E410–E421

PMID

9 Bowen T S, Schuler G, Adams V (2015). Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle, 6(3): 197–207

PMID

10 Carson J A, Baltgalvis K A (2010). Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev, 38(4): 168–176

PMID

11 Choi E, Carruthers K, Zhang L, Thomas N, Battaglino R A, Morse L R, Widrick J J (2013). Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep, 1(6): e00144

PMID

12 Consul N, Guo X, Coker C, Lopez-Pintado S, Hibshoosh H, Zhao B, Kalinsky K, Acharyya S (2016). Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study. Clin Med Insights Oncol, 10: 83–94

PMID

13 Crawford J, Prado C M, Johnston M A, Gralla R J, Taylor R P, Hancock M L, Dalton J T (2016). Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep, 18(6): 37

PMID

14 Deboer M D (2009). Animal models of anorexia and cachexia. Expert Opin Drug Discov, 4(11): 1145–1155

PMID

15 Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura L A (2012). Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients. J Hosp Palliat Nurs, 14(6): 397–402

PMID

16 Dobs A S, Boccia R V, Croot C C, Gabrail N Y, Dalton J T, Hancock M L, Johnston M A, Steiner M S (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol, 14(4): 335–345

PMID

17 Eley H L, Russell S T, Tisdale M J (2007). Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J, 407(1): 113–120

PMID

18 Fearon K, Strasser F, Anker S D, Bosaeus I, Bruera E, Fainsinger R L, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos V E (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 12(5): 489–495

PMID

19 Fukawa T, Yan-Jiang B C, Min-Wen J C, Jun-Hao E T, Huang D, Qian C N, Ong P, Li Z, Chen S, Mak S Y, Lim W J, Kanayama H O, Mohan R E, Wang R R, Lai J H, Chua C, Ong H S, Tan K K, Ho Y S, Tan I B, Teh B T, Shyh-Chang N (2016). Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med, 22(6): 666–671

PMID

20 Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K, Petruzelka L, Apte R N, Mohanty P, Stecher M, Simard J, de Gramont A (2017). MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 18(2): 192–201

PMID

21 Islam-Ali B, Khan S, Price S A, Tisdale M J (2001). Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer, 85(5): 758–763

PMID

22 Jatoi A, Dakhil S R, Nguyen P L, Sloan J A, Kugler J W, Rowland K M Jr, Soori G S, Wender D B, Fitch T R, Novotny P J, Loprinzi C L (2007). A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer, 110(6): 1396–1403

PMID

23 Karayiannakis A J, Syrigos K N, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res, 21(2B): 1355–1358

PMID

24 Li Y P, Reid M B (2000). NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol, 279(4): R1165–R1170

PMID

25 Lok C (2015). Cachexia: The last illness. Nature, 528(7581): 182–183

PMID

26 Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, Riccobon A, Derni S, Pallotti G, Amadori D (1997). Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer, 5(2): 130–135

PMID

27 McLean J B, Moylan J S, Andrade F H (2014). Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes. Front Physiol, 5: 503

PMID

28 Monitto C L, Dong S M, Jen J, Sidransky D (2004). Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res, 10(17): 5862–5869

PMID

29 Mueller T C, Bachmann J, Prokopchuk O, Friess H, Martignoni M E (2016). Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans? BMC Cancer, 16(1): 75

PMID

30 Na Y J, Baek H S, Ahn S M, Shin H J, Chang I S, Hwang J S (2007). [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol, 74(5): 780–786

PMID

31 Narsale A A, Carson J A (2014). Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care, 8(4): 321–327

PMID

32 National Cancer Institute (2011). Tackling the Conundrum of Cachexia in Cancer. Accessed in 2018, from https://www.cancer.gov/about-cancer/treatment/research/cachexia.

33 Onesti J K, Guttridge D C (2014). Inflammation based regulation of cancer cachexia. BioMed Res Int, 2014: 168407

PMID

34 Pagan J, Seto T, Pagano M, Cittadini A (2013). Role of the ubiquitin proteasome system in the heart. Circ Res, 112(7): 1046–1058

PMID

35 Pasut A, Jones A E, Rudnicki M A (2013). Isolation and culture of individual myofibers and their satellite cells from adult skeletal muscle. J Vis Exp, (73): e50074

PMID

36 Patel H J, Patel B M (2017). TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci, 170: 56–63

PMID

37 Penafuerte C A, Gagnon B, Sirois J, Murphy J, MacDonald N, Tremblay M L (2016). Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br J Cancer, 114(6): 680–687

PMID

38 Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G, Zechner R, Wagner E F (2014). A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab, 20(3): 433–447

PMID

39 Petruzzelli M, Wagner E F (2016). Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev, 30(5): 489–501

PMID

40 Porporato P E (2016). Understanding cachexia as a cancer metabolism syndrome. Oncogenesis, 5(2): e200

PMID

41 Puppa M, Narsale A, Rose-John S, Carson J (2014). Trans IL-6 signaling and suppressed muscle protein synthesis with cancer. FASEB J, 28(1)

42 Russell S T, Sanders P M, Tisdale M J (2006). Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett, 231(2): 290–294

PMID

43 Sakuma K, Yamaguchi A (2012). Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle, 3(2): 77–94

PMID

44 Sandri M (2013). Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol, 45(10): 2121–2129

PMID

45 Shiono M, Huang K, Downey R J, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk A C, Inoue A, Halmos B, Acharyya S (2016). An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Med, 5(9): 2641–2648

PMID

46 Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A (2013). Cancer cachexia--pathophysiology and management. J Gastroenterol, 48(5): 574–594

PMID

47 Temel J S, Abernethy A P, Currow D C, Friend J, Duus E M, Yan Y, Fearon K C (2016). Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol, 17(4): 519–531

PMID

48 Waning D L, Mohammad K S, Reiken S, Xie W, Andersson D C, John S, Chiechi A, Wright L E, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi M S, Witzmann F A, Zhen G, Wang X, Cao X, Roodman G D, Marks A R, Guise T A (2015). Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med, 21(11): 1262–1271

PMID

49 Wieland B M, Stewart G D, Skipworth R J, Sangster K, Fearon K C, Ross J A, Reiman T J, Easaw J, Mourtzakis M, Kumar V, Pak B J, Calder K, Filippatos G, Kremastinos D T, Palcic M, Baracos V E (2007). Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res, 13(17): 4984–4992

PMID

50 Winbanks C E, Murphy K T, Bernardo B C, Qian H, Liu Y, Sepulveda P V, Beyer C, Hagg A, Thomson R E, Chen J L, Walton K L, Loveland K L, McMullen J R, Rodgers B D, Harrison C A, Lynch G S, Gregorevic P (2016). Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci Transl Med, 8(348): 348ra98

PMID

51 Wu C, Fernandez S A, Criswell T, Chidiac T A, Guttridge D, Villalona-Calero M, Bekaii-Saab T S (2013). Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas, 42(5): 813–818

PMID

52 Yoshida T, Galvez S, Tiwari S, Rezk B M, Semprun-Prieto L, Higashi Y, Sukhanov S, Yablonka-Reuveni Z, Delafontaine P (2013). Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem, 288(33): 23823–23832

PMID

53 Zhou X, Wang J L, Lu J, Song Y, Kwak K S, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet W S, Lacey D L, Goldberg A L, Han H Q (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell, 142(4): 531–543

PMID